Alliqua BioMedical Company Profile (NASDAQ:ALQA)

About Alliqua BioMedical (NASDAQ:ALQA)

Alliqua BioMedical logoAlliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company's businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company's commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALQA
  • CUSIP: N/A
  • Web: www.alliqua.com
Capitalization:
  • Market Cap: $15.68 million
  • Outstanding Shares: 45,975,000
Average Prices:
  • 50 Day Moving Avg: $0.38
  • 200 Day Moving Avg: $0.52
  • 52 Week Range: $0.32 - $1.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.59
  • P/E Growth: -0.0400
Sales & Book Value:
  • Annual Revenue: $18.88 million
  • Price / Sales: 0.78
  • Book Value: $0.80 per share
  • Price / Book: 0.40
Profitability:
  • EBIDTA: ($20,240,000.00)
  • Net Margins: -145.99%
  • Return on Equity: -75.87%
  • Return on Assets: -49.06%
Debt:
  • Current Ratio: 0.43%
  • Quick Ratio: 0.29%
Misc:
  • Average Volume: 410,450 shs.
  • Beta: 0.99
  • Short Ratio: 0.94
 

Frequently Asked Questions for Alliqua BioMedical (NASDAQ:ALQA)

What is Alliqua BioMedical's stock symbol?

Alliqua BioMedical trades on the NASDAQ under the ticker symbol "ALQA."

How were Alliqua BioMedical's earnings last quarter?

Alliqua BioMedical, Inc. (NASDAQ:ALQA) posted its earnings results on Tuesday, May, 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.04. The firm had revenue of $4.59 million for the quarter, compared to analyst estimates of $4.62 million. Alliqua BioMedical had a negative return on equity of 75.87% and a negative net margin of 145.99%. Alliqua BioMedical's revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.25) EPS. View Alliqua BioMedical's Earnings History.

When will Alliqua BioMedical make its next earnings announcement?

Alliqua BioMedical is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Alliqua BioMedical.

Where is Alliqua BioMedical's stock going? Where will Alliqua BioMedical's stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for Alliqua BioMedical's shares. Their forecasts range from $1.25 to $2.00. On average, they expect Alliqua BioMedical's share price to reach $1.58 in the next year. View Analyst Ratings for Alliqua BioMedical.

Who are some of Alliqua BioMedical's key competitors?

Who are Alliqua BioMedical's key executives?

Alliqua BioMedical's management team includes the folowing people:

  • Jerome B. Zeldis M.D. Ph.D., Chairman of the Board
  • David Ian Johnson, President, Chief Executive Officer, Director
  • Brian M. Posner CPA, Chief Financial Officer, Treasurer, Secretary
  • Bradford Barton, Chief Operating Officer
  • Nino Pionati, Chief Strategy & Marketing Officer
  • Winston Kung, Director
  • Gary C. Restani, Director
  • Mark T. Wagner, Director
  • Joseph M. Leone, Independent Director
  • Jeffrey Sklar M.D., Independent Director

Who owns Alliqua BioMedical stock?

Alliqua BioMedical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (12.06%), Sabby Management LLC (6.07%), Tekla Capital Management LLC (0.00%), Renaissance Technologies LLC (0.00%), KCG Holdings Inc. (0.00%) and Vanguard Group Inc. (0.00%). Company insiders that own Alliqua BioMedical stock include Bradford Barton, Brian M Posner, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis, Mark T Wagner and Pellegrino Pionati. View Institutional Ownership Trends for Alliqua BioMedical.

Who bought Alliqua BioMedical stock? Who is buying Alliqua BioMedical stock?

Alliqua BioMedical's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sabby Management LLC, KCG Holdings Inc., Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought Alliqua BioMedical stock in the last two years include Bradford Barton, Brian M Posner, Corp /De/ Celgene, David Ian Johnson, Jerome B Zeldis, Mark T Wagner and Pellegrino Pionati. View Insider Buying and Selling for Alliqua BioMedical.

How do I buy Alliqua BioMedical stock?

Shares of Alliqua BioMedical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alliqua BioMedical's stock price today?

One share of Alliqua BioMedical stock can currently be purchased for approximately $0.32.


MarketBeat Community Rating for Alliqua BioMedical (NASDAQ ALQA)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Alliqua BioMedical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alliqua BioMedical (NASDAQ:ALQA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.58 (396.97% upside)

Analysts' Ratings History for Alliqua BioMedical (NASDAQ:ALQA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017HC WainwrightSet Price TargetBuy$2.00LowView Rating Details
4/11/2017Cowen and CompanyReiterated RatingOutperform$1.50LowView Rating Details
3/8/2017Chardan CapitalLower Price TargetBuy -> Buy$2.00 -> $1.25HighView Rating Details
2/26/2016Northland SecuritiesLower Price TargetOutperform$7.00 -> $3.00N/AView Rating Details
2/26/2016Craig HallumLower Price TargetBuy$3.00N/AView Rating Details
2/24/2016Royal Bank Of CanadaLower Price TargetOutperform$6.00 -> $3.00N/AView Rating Details
(Data available from 6/24/2015 forward)

Earnings

Earnings History for Alliqua BioMedical (NASDAQ:ALQA)
Earnings by Quarter for Alliqua BioMedical (NASDAQ:ALQA)
Earnings History by Quarter for Alliqua BioMedical (NASDAQ ALQA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017        
5/9/2017Q1 2017($0.13)($0.17)$4.62 million$4.59 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.19)($0.18)$5.18 million$4.94 millionViewListenView Earnings Details
11/4/2016Q3 2016($0.24)($0.20)$4.85 million$4.87 millionViewN/AView Earnings Details
8/9/2016Q216($0.27)$0.05$5.38 million$5.50 millionViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.28)$4.99 million$4.60 millionViewListenView Earnings Details
2/23/2016Q4($0.28)($0.18)$5.30 million$4.80 millionViewListenView Earnings Details
11/5/2015Q315($0.29)($0.25)$5.44 million$5.00 millionViewN/AView Earnings Details
8/6/2015Q215($0.30)($0.27)$2.85 million$3.10 millionViewN/AView Earnings Details
5/14/2015Q115($0.34)($0.34)$2.37 million$2.10 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.34)$1.77 million$1.66 millionViewN/AView Earnings Details
10/30/2014Q3 14($0.31)($0.33)$1.49 millionViewN/AView Earnings Details
3/24/2014Q313($0.23)($1.68)$0.40 million$0.47 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alliqua BioMedical (NASDAQ:ALQA)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alliqua BioMedical (NASDAQ:ALQA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alliqua BioMedical (NASDAQ:ALQA)
Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 26.19%
Insider Trades by Quarter for Alliqua BioMedical (NASDAQ:ALQA)
Institutional Ownership by Quarter for Alliqua BioMedical (NASDAQ:ALQA)
Insider Trades by Quarter for Alliqua BioMedical (NASDAQ:ALQA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Bradford BartonCOOBuy75,000$0.40$30,000.00View SEC Filing  
4/3/2017David Ian JohnsonInsiderBuy250,000$0.40$100,000.00View SEC Filing  
4/3/2017Mark T WagnerDirectorBuy62,500$0.40$25,000.00View SEC Filing  
2/27/2017Corp /De/ CelgeneMajor ShareholderBuy4,000,000$0.50$2,000,000.00View SEC Filing  
2/27/2017Jerome B ZeldisDirectorBuy400,000$0.50$200,000.00View SEC Filing  
11/9/2015Brian M PosnerCFOBuy5,000$3.04$15,200.00View SEC Filing  
11/6/2015Bradford BartonCOOBuy5,000$2.97$14,850.00View SEC Filing  
11/6/2015David Ian JohnsonCEOBuy8,650$2.92$25,258.00View SEC Filing  
11/6/2015Jerome B ZeldisDirectorBuy14,000$2.91$40,740.00View SEC Filing  
11/6/2015Pellegrino PionatiInsiderBuy10,000$2.95$29,500.00View SEC Filing  
8/10/2015Brian M PosnerCFOBuy2,500$5.02$12,550.00View SEC Filing  
6/8/2015Bradford BartonCOOBuy3,000$5.25$15,750.00View SEC Filing  
5/27/2015David Ian JohnsonCEOBuy10,000$4.65$46,500.00View SEC Filing  
5/20/2015Brian M PosnerCFOBuy2,500$4.34$10,850.00View SEC Filing  
5/4/2015Corp /De/ CelgeneMajor ShareholderBuy659,340$4.55$2,999,997.00View SEC Filing  
9/15/2014Brian M PosnerCFOBuy2,000$4.94$9,880.00View SEC Filing  
5/13/2014Brian M PosnerCFOBuy3,000$6.92$20,760.00View SEC Filing  
4/14/2014Corp /De/ CelgeneMajor ShareholderBuy714,286$7.00$5,000,002.00View SEC Filing  
5/21/2013Kenneth L LondonerDirectorBuy219,500$0.07$15,365.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alliqua BioMedical (NASDAQ:ALQA)
Latest Headlines for Alliqua BioMedical (NASDAQ:ALQA)
Source:
DateHeadline
americanbankingnews.com logoAlliqua BioMedical (ALQA) versus Eli Lilly and Company (LLY) Financial Survey
www.americanbankingnews.com - June 22 at 4:44 PM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Potential Breaches ... - PR Newswire (press release)
www.prnewswire.com - June 22 at 3:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 22 at 12:22 PM
nasdaq.com logoAlliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with ... - Nasdaq
www.nasdaq.com - June 19 at 8:34 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with New Equipment Financing Programs
finance.yahoo.com - June 19 at 3:33 PM
globenewswire.com logoAlliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with ... - GlobeNewswire (press release)
globenewswire.com - June 19 at 7:34 AM
finance.yahoo.com logoETFs with exposure to Alliqua BioMedical, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 3:23 PM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Expected to Announce Quarterly Sales of $5.08 Million
www.americanbankingnews.com - June 4 at 7:52 AM
americanbankingnews.com logoZacks: Brokerages Expect Alliqua Biomedical Inc (ALQA) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 2 at 6:22 PM
finance.yahoo.com logoETFs with exposure to Alliqua BioMedical, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 3:18 PM
finance.yahoo.com logoETFs with exposure to Alliqua BioMedical, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 3:28 PM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) PT Set at $2.00 by HC Wainwright
www.americanbankingnews.com - May 13 at 6:58 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. :ALQA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 4:03 PM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Expected to Announce Quarterly Sales of $4.97 Million
www.americanbankingnews.com - May 11 at 11:38 AM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 9 at 1:38 PM
finance.yahoo.com logoInvestor Network: Alliqua, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 9:20 AM
finance.yahoo.com logoAlliqua BioMedical, Inc. Reports First Quarter of Fiscal Year 2017 Financial Results
finance.yahoo.com - May 9 at 9:20 AM
finance.yahoo.com logoAlliqua reports 1Q loss
finance.yahoo.com - May 9 at 9:20 AM
americanbankingnews.com logoAlliqua Biomedical (ALQA) Receiving Favorable News Coverage, Study Finds
www.americanbankingnews.com - May 2 at 2:08 PM
americanbankingnews.com logoAlliqua Biomedical (ALQA) Given Coverage Optimism Score of 0.46
www.americanbankingnews.com - April 29 at 9:08 AM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Short Interest Down 29.7% in April
www.americanbankingnews.com - April 29 at 7:34 AM
americanbankingnews.com logoAlliqua Biomedical (ALQA) Getting Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 26 at 3:12 PM
americanbankingnews.com logoAlliqua Biomedical (ALQA) Given Daily Media Impact Rating of 0.44
www.americanbankingnews.com - April 18 at 11:04 AM
americanbankingnews.com logoCowen and Company Reaffirms "Outperform" Rating for Alliqua Biomedical Inc (ALQA)
www.americanbankingnews.com - April 14 at 5:27 PM
americanbankingnews.com logoAlliqua Biomedical (ALQA) Given Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - April 14 at 3:56 PM
nasdaq.com logoAlliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain ... - Nasdaq
www.nasdaq.com - April 13 at 3:39 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance
finance.yahoo.com - April 12 at 8:29 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
finance.yahoo.com - April 12 at 11:59 AM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 4:35 PM
americanbankingnews.com logoHC Wainwright Trims Alliqua Biomedical Inc (ALQA) Target Price to $1.50
www.americanbankingnews.com - April 7 at 7:24 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. to Present New Data at the Spring 2017 Symposium on Advanced Wound Care
finance.yahoo.com - April 7 at 3:29 PM
streetinsider.com logoAlliqua (ALQA) to Present New Data at SAWC - StreetInsider.com
www.streetinsider.com - April 7 at 7:59 AM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) COO Buys $30,000.00 in Stock
www.americanbankingnews.com - April 4 at 1:10 PM
americanbankingnews.com logoDavid Ian Johnson Buys 250,000 Shares of Alliqua Biomedical Inc (ALQA) Stock
www.americanbankingnews.com - April 4 at 1:10 PM
finance.yahoo.com logoAlliqua BioMedical, Inc. Announces Closing of Approximately $3.8 Million Public Offering
finance.yahoo.com - April 3 at 8:46 PM
biz.yahoo.com logoALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat
biz.yahoo.com - March 31 at 3:36 PM
finance.yahoo.com logoAlliqua BioMedical, SCANA Drop into Wednesday’s 52-Week Low Club
finance.yahoo.com - March 29 at 8:37 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Morgan Stanley, Twitter, Exar, RH, Skechers, Atossa, Alliqua - Nasdaq
www.nasdaq.com - March 29 at 3:34 PM
nasdaq.com logoMid-Day Market Update: Crude Oil Up 1.5%; Alliqua Biomedical Shares Slide - Nasdaq
www.nasdaq.com - March 29 at 3:34 PM
globenewswire.com logoAlliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - March 29 at 3:34 PM
streetinsider.com logoAlliqua (ALQA) Plans Offering of Common Stock
www.streetinsider.com - March 29 at 10:35 AM
us.rd.yahoo.com logoAlliqua BioMedical, Inc. Announces Pricing of Public Offering of Common Stock
us.rd.yahoo.com - March 29 at 10:35 AM
us.rd.yahoo.com logoAlliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock
us.rd.yahoo.com - March 28 at 8:27 PM
biz.yahoo.com logoALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 23 at 3:41 PM
nasdaq.com logoAlliqua BioMedical, Inc. Announces the Publication of a Peer-reviewed Study Examining the Use of MIST Therapy for ... - Nasdaq
www.nasdaq.com - March 22 at 3:30 PM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 22 at 8:19 AM
us.rd.yahoo.com logoAlliqua BioMedical, Inc. Announces the Publication of a Peer-reviewed Study Examining the Use of MIST Therapy for Deep Tissue Pressure Injuries
us.rd.yahoo.com - March 20 at 3:47 PM
americanbankingnews.com logoAlliqua Biomedical Inc (ALQA) Upgraded to “Buy” at Zacks Investment Research
www.americanbankingnews.com - March 18 at 3:33 PM
finance.yahoo.com logoALLIQUA BIOMEDICAL, INC. Financials
finance.yahoo.com - March 18 at 3:23 PM
barrons.com logo[$$] Celgene Shows Savvy as Gilead Keeps Backsliding
www.barrons.com - March 16 at 4:59 PM

Social

Chart

Alliqua BioMedical (ALQA) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by MarketBeat.com Staff